CanniMed Therapeutics Inc. Announces Quarterly Results Release Date
March 16 2018 - 7:00AM
Business Wire
CanniMed Therapeutics Inc. (TSX:CMED) (“CanniMed” or the
“Company”) announces that it plans to release its financial results
for the three months ended January 31, 2018 before markets open on
Monday, March 19, 2018.
About CanniMed Therapeutics Inc.
CanniMed is a Canadian-based, international plant
biopharmaceutical company and a leader in the Canadian medical
cannabis industry, with 17 years of pharmaceutical cannabis
cultivation experience, state-of-the-art, GMP-compliant production
process and world class research and development platforms with a
wide range of pharmaceutical-grade cannabis products.
CanniMed, through its subsidiaries, was the first producer to be
licensed under the Marihuana for Medical Purposes Regulations, the
predecessor to the current Access to Cannabis for Medical Purposes
Regulations. It was the sole supplier to Health
Canada under the former medical marijuana system for 13 years
and has been producing safe and consistent medical marijuana for
thousands of Canadian patients, with no incident of product
diversion or recalls.
For more information, please visit our
websites: www.cannimed.ca (patients)
and www.cannimedtherapeutics.com (investors).
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180316005185/en/
CanniMed Therapeutics Inc.Dara Willis,
416-836-9272dhw@cannimed.com